


REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1D01
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733



In re Application of

Application Number

09/557 001

Filed

APR. 20, 00

Paper No.

11

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. 6573,402, page, _____ line _____.

United States Patent Number _____, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

Kelm Rodriguez

Signature

KEVIN Rodriguez

Typed or printed name

S-16-05

Date

Registration Number, if applicable

(703) 418-2777

Telephone Number

FOR PTO USE ONLY	
RECEIVED	
Approved by:	MAY 16 2005 (Initials)
Unit:	File Information Unit

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.



US006573402B1

(12) **United States Patent**
Gwag et al.

(10) Patent No.: **US 6,573,402 B1**
(45) Date of Patent: **Jun. 3, 2003**

(54) **COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING NEURODEGENERATION IN ACUTE AND CHRONIC INJURIES IN THE CENTRAL NERVOUS SYSTEM**

(75) Inventors: **Byoung Joo Gwag**, Seoul (KR); **Young Ae Lee**, Suwon-si (KR); **Bo Rum Ryu**, Suwon-si (KR); **Sung Hwa Yoon**, Suwon-si (KR); **Ho Sang Moon**, Suwon-si (KR)

(73) Assignee: **Neurotech Co., Ltd.**, Kyungki-do (KR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/206,772**

(22) Filed: **Jul. 29, 2002**

Related U.S. Application Data

(63) Continuation of application No. 09/557,001, filed on Apr. 20, 2000, now abandoned.

(51) Int. Cl.⁷ **C07C 205/00**

(52) U.S. Cl. **562/435**

(58) Field of Search **562/435**

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,632,760 A * 1/1972 Shen et al.

FOREIGN PATENT DOCUMENTS

DE	2 031 227	1/1971
EP	122 827	10/1984
GB	1268465	3/1972
JP	54-125632	5/1979
JP	60-237041	4/1986
WO	WO 86/03199	5/1986
WO	WO 94/13663	6/1994

OTHER PUBLICATIONS

International Preliminary Examination Report for PCT/KR 00/00366, Aug. 23, 2002.
Anderson and Hall, *Ann. Emerg. Med.* 22:987-992 (1993).
Anderson, Swartzwelder, and Wilson, *J. Neurophysiol.* 57:1-21 (1987).
Beal, *Ann. Neurol.* 38:357-366 (1995).
Beal, Ferrante, Swartz, and Kowall, *J. Neurosci.* 11:1649-1659 (1991).
Beal, Kowall, Ellison, Mazurek, Swartz, and Martin, *Nature* 321: 168-171 (1986).
Brouillet and Beal, *Neuroreport*. 4:387-390 (1993).
Browne, Ferrante, and Beal, *Brain Pathol.* 9:147-163 (1999).
Bush, Pettingell, Multhaup, Paradis, Vonsattel, Gusella, Beyreuther, Masters, and Tanzi, *Science* 265:1464-1467 (1994).
Chan, *Stroke* 27:1124-1129 (1996).
Choi, *Neurosci* 21:347-375 (1988).
Choi, *Neuron* 1:623-634 (1988).
Choi and Rothman, *Annu Rev Neurosci* 13:171-182 (1990).
Choi, *J. Neurosci* 7:369-379, 1987.

(List continued on next page.)

Primary Examiner—Samuel Barts

Assistant Examiner—Paul A. Zucker

(74) Attorney, Agent, or Firm—Shanks & Herbert

(57) **ABSTRACT**

The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn^{2+} , and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn^{2+} neurotoxicity, and free radical neurotoxicity.

1 Claim, 38 Drawing Sheets

